Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:<ul><li>Introduction (0:00)</li><li>Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)</li><li>HER2-Positive Breast Cancer — Dr Bardia (42:46)</li><li>Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)</li></ul> <a href="https://researchtopractice.com/PostASCO2026/Breast/Video" rel="noopener noreferrer" target="_blank">CME information and select publications</a>

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41) CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:<ul><li>Introduction (0:00)</li><li>Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)</li><li>HER2-Positive Breast Cancer — Dr Bardia (42:46)</li><li>Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)</li></ul> <a href="https://researchtopractice.com/PostASCO2026/Breast/Video" rel="noopener noreferrer">CME information and select publications</a>

Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:<ul><li>Introduction (0:00)</li><li>HER2 History (1:32)</li><li>Cases from the GMO Survey (7:06)</li><li>Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)</li><li>Faculty Case Presentations (31:37)</li><li>Patterns of Care Survey — Part 1 (38:26)</li><li>Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)</li><li>Faculty Case Presentations (54:13)</li></ul> <a href="https://researchtopractice.com/activity/what-clinicians-want-to-know-first-line-and-maintenance-therapy-for-patients-with-er-positive-her2-positive-metastatic-breast-cancer-part-2-of-2/" rel="noopener noreferrer" target="_blank">CME information and select publications</a>

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:Introduction (0:00)HER2 History (1:32)Cases from the GMO Survey (7:06)Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)Faculty Case Presentations (31:37)Patterns of Care Survey — Part 1 (38:26)Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)Faculty Case Presentations (54:13) CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:<ul><li>Introduction (0:00)</li><li>HER2 History (1:32)</li><li>Cases from the GMO Survey (7:06)</li><li>Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)</li><li>Faculty Case Presentations (31:37)</li><li>Patterns of Care Survey — Part 1 (38:26)</li><li>Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)</li><li>Faculty Case Presentations (54:13)</li></ul> <a href="https://researchtopractice.com/activity/what-clinicians-want-to-know-first-line-and-maintenance-therapy-for-patients-with-er-positive-her2-positive-metastatic-breast-cancer-part-2-of-2/" rel="noopener noreferrer">CME information and select publications</a>

ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:<ul><li>Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)</li><li>First-Line Therapy (PD-L1 Negative) (6:53)</li><li>First-Line Therapy (PD-L1 Positive) (23:40)</li><li>Second-Line Therapy (Sequencing) (34:08)</li><li>Adverse Events with TROP2-Targeting ADCs (43:43)</li></ul> <a href="https://researchtopractice.com/mTNBC26/2/Video" rel="noopener noreferrer" target="_blank">CME information and select publications</a>

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43) CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:<ul><li>Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)</li><li>First-Line Therapy (PD-L1 Negative) (6:53)</li><li>First-Line Therapy (PD-L1 Positive) (23:40)</li><li>Second-Line Therapy (Sequencing) (34:08)</li><li>Adverse Events with TROP2-Targeting ADCs (43:43)</li></ul> <a href="https://researchtopractice.com/mTNBC26/2/Video" rel="noopener noreferrer">CME information and select publications</a>

Metastatic Triple-Negative Breast Cancer — Patterns of Care

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:<ul><li>Introduction: ODAC — April 30, 2026 (00:00)</li><li>Adjuvant CDK4/6 Inhibitors (13:03)</li><li>Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)</li><li>Premenopausal Patients (30:52)</li><li>Duration of Adjuvant Endocrine Treatment (38:44)</li><li>Genomic Predictors of Chemotherapy Benefit (47:19)</li><li>Neoadjuvant Treatment (55:13)</li></ul> <a href="https://researchtopractice.com/YIR2025/LocalizedHRPosBC/Video" rel="noopener noreferrer" target="_blank">CME information and select publications</a>

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:Introduction: ODAC — April 30, 2026 (00:00)Adjuvant CDK4/6 Inhibitors (13:03)Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)Premenopausal Patients (30:52)Duration of Adjuvant Endocrine Treatment (38:44)Genomic Predictors of Chemotherapy Benefit (47:19)Neoadjuvant Treatment (55:13) CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:<ul><li>Introduction: ODAC — April 30, 2026 (00:00)</li><li>Adjuvant CDK4/6 Inhibitors (13:03)</li><li>Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)</li><li>Premenopausal Patients (30:52)</li><li>Duration of Adjuvant Endocrine Treatment (38:44)</li><li>Genomic Predictors of Chemotherapy Benefit (47:19)</li><li>Neoadjuvant Treatment (55:13)</li></ul> <a href="https://researchtopractice.com/YIR2025/LocalizedHRPosBC/Video" rel="noopener noreferrer">CME information and select publications</a>

Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3

Outside a protocol setting, a combination of endocrine therapy and trastuzumab provides the best potential risk/benefit profile for women with ER-positive, HER2-positive metastatic disease.

SABCS Spin-Off | 06 - Mackey

Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after AC->TH.

Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after AC-&gt;TH.

SABCS Spin-Off | 06 - Tripathy

BCU 1 | 07 - Norton

BCU 1 | 07 - Muss

BCU 1 | 07 - Sparano

BCU 1 | 07 - Roundtable Discussion

Interview with Harold J Burstein, MD, PhD

BCU 8 | 06 - Burstein

BCU 8 | 06 - Ravdin

BCU 8 | 06 - Livingston

BCU 8 | 06 - Bear

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Share Breast Cancer Update

Sign up to save your podcasts

Breast Cancer Update

Breast Cancer Update episodes

About Breast Cancer Update

Best of Breast Cancer Update

More shows like Breast Cancer Update

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

Lung Cancer Update

Hematologic Oncology Update

Prostate Cancer Update

Gastrointestinal Cancer Update

Gynecologic Oncology Update

Dermatologic Oncology Update

Research To Practice | Oncology Videos

Breastcancer.org Podcast

ASCO Daily News

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

ASCO Guidelines

Harrison's PodClass: Internal Medicine Cases and Board Prep

Oncology Today with Dr Neil Love

Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing